Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Imagine your doctor calls you to discuss the results of your genetic testing. They tell you your results indicate you are ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...
This study identifies 47,350 enhancers active in human neurons during differentiation and links some to genes involved in ...
Monoallelic loss of PTEN and ARID1A is identified in normal colonic epithelium. The resulting haploinsufficient phenotypes ...
This is an important and solid study that examines the role of TFAM, a protein that helps maintain mtDNA, in mtDNA mutator mice. The authors have demonstrated that TFAM's counteractive role in mtDNA ...
Feb. 10, 2025 — Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback